氟维司群-芙仕得幻灯片

维司群作为激素受体阳性转移性乳腺癌的重要治疗选择Р指南РРESMOР中国抗癌协会乳腺癌?诊治指南与规范Р区域Р美国Р欧洲Р中国Р版本Р2014.v3Р2013Р2013Р推荐РРРР Clinical Practice Guidelines in Oncology®. Invasive Breast Cancer v.3. 2014.?Senkus E, et al. Ann Oncol 2013; 24(Suppl 6):vi7-vi23.?中国抗癌协会乳腺癌专业委员会. 中国癌症杂志 2013; 23(8):637-684.РFASLODEX 500 mg (N=362)РPrimary analysisbРPostmenopausal women with advanced breast cancer, progressing or relapsing after one prior endocrine therapyРDisease progression / survivalaРSurvival follow-up analysisРFASLODEX 250 mg (N=374)РFollow-up visits (study treatment)РaAll patients followed for disease progression / survival, regardless of treatment discontinuationРbAfter data cut-off for the primary analysis, all patients enter the survival follow-up phaseРCOmparisoN of FASLODEX In Recurrent or Metastatic Breast CancerР10